Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Dermatol Surg ; 48(5): 551-555, 2022 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-35170541

RESUMEN

BACKGROUND: In total, 2.7 million injectable filler treatments were performed in 2019 in the United States. Although generally considered to be a safe treatment modality, adverse events may occur in rare situations. OBJECTIVE: Analyze serious adverse events from injectable filler treatments, including infections, cutaneous necrosis, blindness, or delayed-onset nodule formation, spanning 11 years for 3 board-certified dermatologists and review their incidence, management, and outcomes. MATERIALS AND METHODS: A retrospective analysis was performed of injectable filler treatments spanning 11 years at a multipractitioner outpatient clinic. Serious adverse events were identified, and treatment measures were documented. A literature search was performed to determine recent trends and outcomes for comparison. RESULTS: Between January 2009 and August 2020, 18,013 mL of injectable filler was administered to 7,659 patients. Of the 18,013 mL administered, 74.1% comprised hyaluronic acid derivatives, 19.19% poly-l-lactic acid, and 6.71% calcium hydroxylapatite. Four serious adverse events were identified. Three events were delayed-onset skin nodule formation. One adverse event was related to vascular compromise and subsequent cutaneous necrosis. After appropriate treatment, all adverse events resolved without significant long-term sequelae. CONCLUSION: Serious adverse events associated with injectable fillers, when performed by board-certified dermatologists, are extremely rare and can be successfully managed with appropriate treatment.


Asunto(s)
Técnicas Cosméticas , Rellenos Dérmicos , Técnicas Cosméticas/efectos adversos , Rellenos Dérmicos/efectos adversos , Durapatita/efectos adversos , Humanos , Ácido Hialurónico/efectos adversos , Necrosis/inducido químicamente , Estudios Retrospectivos , Estados Unidos
2.
J Drugs Dermatol ; 21(5): 517-520, 2022 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-35533024

RESUMEN

BACKGROUND: Background: Skin exposure to ultraviolet radiation (UVR) causes DNA damage, which can lead to mutagenesis, carcinogenesis, cellular death, and photoaging. Signs of photoaging include wrinkling, erythema, skin laxity, uneven skin texture, and hyperpigmentation. Photolyase is an exogenous DNA repair enzyme that can restore DNA integrity when applied topically to human skin. Antioxidants also play a key role in reducing UVR-associated molecular damage. OBJECTIVE: To assess the efficacy and safety of a tinted mineral-based sunscreen containing 10.7% zinc oxide (SPF50) with the active ingredients photolyase, antioxidants (Peptide Q10), and peptides in both protecting and repairing signs of photoaging. METHODS: In an open-label, single-center, 12-week study, patients aged 35–55 years and Fitzpatrick skin phototypes II–IV applied the sunscreen daily for 84 days. VISIA photography was performed at baseline as well as 6- and 12-week follow-ups. At each visit, the investigator and subject evaluated clinical photoaging parameters including overall photodamage, fine lines/wrinkles, coarse lines/wrinkles, skin tone evenness, tactile roughness, and radiance. RESULTS: The Investigator Global Aesthetic Improvement Scale (IGAIS) found that 63% of patients showed improvement at week 6 and 81% at week 12. The Subject Global Aesthetic Improvement Scale (SGAIS) showed 58% and 62.5% of patients reported the appearance of their skin was improved at week 6 and 12, respectively. Overall, there was a statistically significant improvement in skin radiance as well as improvement in overall facial aesthetics reported by both investigators and subjects. CONCLUSION: This tinted mineral based SPF50 sunscreen containing photolyase, antioxidants, and peptides is effective at repairing some clinical signs of photoaging and is well-tolerated for daily use. J Drugs Dermatol. 2022;21(5):517-520. doi:10.36849/JDD.6503.


Asunto(s)
Desoxirribodipirimidina Fotoliasa , Envejecimiento de la Piel , Administración Cutánea , Antioxidantes/farmacología , Humanos , Protectores Solares , Resultado del Tratamiento , Rayos Ultravioleta/efectos adversos
3.
J Anim Sci ; 1022024 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-38898575

RESUMEN

The study objective was to investigate the effect of repeated hypothalamic-pituitary-adrenal (HPA) axis stimulation using synthetic adrenocorticotropic hormone (ACTH) intramuscular injections on hair cortisol concentration, growth, and behavior in preweaned dairy calves. Twenty-seven Holstein calves were assigned to nine triads (based on sex and birth order) and randomly assigned to 1 of 3 treatments: 1) control (CON; 2 mL saline weekly); 2) moderate (MOD; alternating Cosyntropin [2 mcg/kg body weight (BW)] and saline weekly); or 3) frequent (FREQ; Cosyntropin [2 mcg/kg BW] weekly). Calves received their first injection on study day 0 (7 ±â€…1 d of age). Hair was collected from the tail switch between days -5 and -3 (baseline), 21, and 49 and analyzed for cortisol concentration. To verify the endogenous cortisol release by Cosyntropin during the treatment period, saliva was collected on days 0, 14, 28, and 42 before injection and every 15 min for 2 h after injection for analysis of salivary cortisol concentration. Calves were fitted with accelerometers to continuously monitor lying time, number of lying bouts, and lying bout duration throughout the study. Growth measures (BW, hip height, hip width) were recorded weekly. Data were analyzed using repeated measures ANOVA (SAS, Version 9.4), and models included the fixed effects of treatment, time (min or study day), and interaction between treatment and time. Temperature humidity index was included as a continuous covariate in all models. We observed a treatment × min interaction (P < 0.0001), whereby salivary cortisol concentration was lower in CON calves compared to MOD and FREQ calves 15 to 120 min postinjection. While hair cortisol concentration was not influenced by treatment, concentration decreased from day 21 (1.28 ±â€…0.03 ng/mL) to 49 (0.93 ±â€…0.03 ng/mL). Average BW was similar across treatments (CON [59.4 ±â€…1.09 kg], MOD [58.6 ±â€…0.98 kg], and FREQ [57.6 ±â€…0.96 kg]; P = 0.50). There was no evidence to suggest a difference in average daily lying time (CON [18.5 ±â€…0.23 h/d], MOD [18.6 ±â€…0.23 h/d], and FREQ [18.5 ±â€…0.23 h/d]; P = 0.99). These results suggest that repeated HPA axis stimulation through Cosyntropin administration increased salivary cortisol concentration, but did not influence hair cortisol concentration, growth, or behavior in preweaned dairy calves.


Measures to quantify long-term or chronic stress in livestock are limited. The amount of cortisol (a stress hormone) deposited in the hair has been used as a noninvasive measure of long-term stress in some livestock species; however, few studies have investigated its use in young dairy calves. The objective of this study was to determine the efficacy of hair cortisol as a less invasive measure of stress in calves. Calves were either injected with saline (control) or Cosyntropin, a hormone that activates the stress response system, at different frequencies during the first two months of life. Cosyntropin injection increased salivary cortisol concentration (an indicator of acute stress) but did not increase hair cortisol concentration. There was no evidence to suggest a significant effect of treatment on calf growth. Calf behavior was similar between treatment groups. These results suggest that the method used to activate the stress response system in this study was sufficient to induce an acute stress response in calves (as indicated by increased salivary cortisol concentration), and more research is needed to investigate measures of chronic stress in young dairy calves.


Asunto(s)
Cabello , Hidrocortisona , Sistema Hipotálamo-Hipofisario , Sistema Hipófiso-Suprarrenal , Animales , Bovinos/fisiología , Hidrocortisona/metabolismo , Cabello/química , Femenino , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Masculino , Conducta Animal/efectos de los fármacos , Cosintropina/farmacología , Cosintropina/administración & dosificación , Saliva/química , Inyecciones Intramusculares/veterinaria
4.
Front Med (Lausanne) ; 10: 1178872, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37324157

RESUMEN

Introduction: This study aims to investigate the acceptance, hesitance and attitudes of infertile female patients toward the COVID-19 vaccination. Methods: An anonymous cross-sectional online survey was conducted between 28th of January to 10th of August 2022. The questionnaire consisted of 35 questions on demographics, COVID-19 vaccination status, prior concerns of the vaccinated participants and reasons for not vaccinating among unvaccinated participants, and factors influencing the decision not to vaccinate. Results: Of 406 participants who answered all questions, 92.1% reported having received at least one dose of COVID-19 vaccine, 7.9% were unvaccinated. Factors associated with the decision for vaccination were full time or part time employment (p = 0.05), high trust in the principle of vaccination (p < 0.001), high willingness for other vaccination during fertility treatment (p < 0.001) and risk factors for severe COVID-19 (p = 0.007). Concerns about directly occurring adverse effects after vaccination (42.0%), about impact on own fertility (21.9%) or on the fertility treatment (27.5%) were the main concerns beforehand of vaccinated participants. Correlations between fertility concerns and mistrust in the general principle of vaccination were found. Beside general health concerns, unvaccinated participants reported fears about fertility impairment as the most important arguments against a COVID-19 vaccination (median of 5.0 on a five-point-Likert scale). Conclusion: Both vaccinated and unvaccinated participants stated having concerns and fears about side effects of the COVID-19 vaccination on their fertility. To increase patients' trust in medical recommendations, such as vaccination, to avoid mistrust in the medical system and to maintain patient's compliance, there should be additional educational services that address infertile patients and their needs.

5.
JAMA Dermatol ; 160(6): 672-673, 2024 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-38630488

RESUMEN

A 38-year-old man presented with numerous pink-yellow firm papules and nodules on the bilateral elbows for 10 years spreading to the hands and knees in the past year. What is your diagnosis?


Asunto(s)
Progresión de la Enfermedad , Humanos , Masculino , Persona de Mediana Edad , Biopsia , Enfermedad Crónica , Diagnóstico Diferencial , Piel/patología
7.
Clin Neuropharmacol ; 27(3): 119-23, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15190234

RESUMEN

OBJECTIVES: To determine the rate of and identify reasons for discontinuation of entacapone treatment in Parkinson disease patients. METHODS: A retrospective study design was used, including medical record reviews and telephone call to the patient as needed. RESULTS: Two hundred and twenty-two Parkinson disease patients were started on entacapone over a period of 3 years. One hundred and twenty-two patients (56%) had discontinued the medication by the end of the follow up period. Reasons for discontinuation included lack of efficacy (46%), worsening of parkinsonian symptoms (28%), worsened cognition (20%), dyskinesia (17%), nausea (11%), diarrhea (9%), cost (4%), other side effect (8%), and other, non-medication related reasons (19%). Presence of wearing off at the time of initial treatment and male sex were associated with decreased dropout rates, while the presence of orthostatic hypotension increased the likelihood of discontinuation. Patient age, disease duration, Hoehn and Yahr stage, Unified Parkinson's Disease Rating Scale section II score, presence of dementia, hallucinations, dyskinesias, or depression, number of daily L-dopa doses, and concomitant treatment with dopamine agonists did not affect dropout rate. CONCLUSIONS: Lack of efficacy seems to be the main reason for entacapone discontinuation. Male patients with wearing off and no orthostatic hypotension seem to tolerate the medication better. Advanced disease stage, presence of cognitive dysfunction, and presence of dyskinesia should not necessarily preclude patients from being treated with entacapone, when otherwise indicated.


Asunto(s)
Antiparkinsonianos/uso terapéutico , Catecoles/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Factores de Riesgo , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Examen Neurológico , Nitrilos , Enfermedad de Parkinson/fisiopatología , Estudios Prospectivos , Estudios Retrospectivos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA